{
    "id": 23862,
    "fullName": "ERBB2 S653C",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) S653C lies within the transmembrane domain of the Erbb2 (Her2) protein (PMID: 30449325). S653C results in constitutive activation of Erbb2 (Her2) and phosphorylation of Shc and Erk in cell culture (PMID: 24971884) and leads to increased cell survival as compared to wild-type Erbb2 (Her2) in culture (PMID: 30449325).",
            "references": [
                {
                    "id": 13125,
                    "pubMedId": 30449325,
                    "title": "Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30449325"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 6134,
                    "pubMedId": 24971884,
                    "title": "Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24971884"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "S653C",
    "createDate": "06/28/2016",
    "updateDate": "10/21/2019",
    "referenceTranscriptCoordinates": {
        "id": 170747,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39723330C>G",
        "cDna": "c.1958C>G",
        "protein": "p.S653C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7176,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S653C demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).",
            "molecularProfile": {
                "id": 24587,
                "profileName": "ERBB2 S653C"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6134,
                    "pubMedId": 24971884,
                    "title": "Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24971884"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7175,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884).",
            "molecularProfile": {
                "id": 24587,
                "profileName": "ERBB2 S653C"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6134,
                    "pubMedId": 24971884,
                    "title": "Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24971884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7174,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884).",
            "molecularProfile": {
                "id": 24587,
                "profileName": "ERBB2 S653C"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6134,
                    "pubMedId": 24971884,
                    "title": "Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24971884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15745,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C demonstrated resistance when treated with Nolvadex (tamoxifen) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15855,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15753,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C demonstrated resistance when treated with GDC-0810 in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15862,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Capivasertib (AZD5363) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 4452,
                "therapyName": "Capivasertib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15848,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of VX-11e did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 7755,
                "therapyName": "Fulvestrant + VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15749,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C demonstrated resistance when treated with Faslodex (fulvestrant) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15885,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15764,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Nerlynx (neratinib) results in restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15810,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C were resistant to the combination therapy of Faslodex (fulvestrant) and Ibrance (palbociclib) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15837,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mekinist (trametinib) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 7754,
                "therapyName": "Fulvestrant + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24587,
            "profileName": "ERBB2 S653C",
            "profileTreatmentApproaches": [
                {
                    "id": 9831,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB2 S653C"
                },
                {
                    "id": 9832,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB2 S653C"
                }
            ]
        },
        {
            "id": 31189,
            "profileName": "ERBB2 S653C ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170748,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39723330C>G",
            "cDna": "c.1958C>G",
            "protein": "p.S653C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170747,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39723330C>G",
            "cDna": "c.1958C>G",
            "protein": "p.S653C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}